GRASSILLI, EMANUELA
 Distribuzione geografica
Continente #
NA - Nord America 2.917
EU - Europa 2.402
AS - Asia 269
Continente sconosciuto - Info sul continente non disponibili 11
AF - Africa 4
SA - Sud America 3
Totale 5.606
Nazione #
US - Stati Uniti d'America 2.863
DE - Germania 1.132
IT - Italia 569
SE - Svezia 231
CN - Cina 187
GB - Regno Unito 127
UA - Ucraina 110
DK - Danimarca 58
CA - Canada 54
AT - Austria 37
VN - Vietnam 31
BE - Belgio 29
IE - Irlanda 29
FI - Finlandia 26
FR - Francia 19
RU - Federazione Russa 18
HK - Hong Kong 17
TR - Turchia 14
EU - Europa 11
IN - India 10
RS - Serbia 5
CH - Svizzera 4
HU - Ungheria 3
IR - Iran 3
JP - Giappone 3
MU - Mauritius 3
CL - Cile 2
KR - Corea 2
NL - Olanda 2
BG - Bulgaria 1
BR - Brasile 1
CZ - Repubblica Ceca 1
RO - Romania 1
SC - Seychelles 1
SG - Singapore 1
TW - Taiwan 1
Totale 5.606
Città #
Ann Arbor 1.312
Frankfurt am Main 1.037
Milan 287
Wilmington 243
Chandler 159
Fairfield 134
Dearborn 114
Jacksonville 97
Houston 91
Woodbridge 91
Ashburn 84
Princeton 57
New York 50
Cambridge 46
Seattle 44
Mcallen 43
Vienna 35
Nanjing 30
Brussels 29
Dublin 29
Guangzhou 24
Altamura 18
Boardman 17
Lachine 17
Shanghai 17
Hong Kong 16
Lawrence 16
Ottawa 16
Segrate 13
Shenyang 13
Beijing 11
Nanchang 11
Kunming 10
Sacramento 10
San Diego 10
Toronto 10
Turin 10
Auburn Hills 9
Dong Ket 9
Edmonton 9
Lissone 9
London 9
Monza 9
Zhengzhou 9
Hebei 8
Tianjin 8
Changsha 7
Fremont 6
Helsinki 6
Jiaxing 6
Jinan 6
Council Bluffs 5
Halle 5
Los Angeles 5
Napoli 5
Taizhou 5
Terni 5
Andover 4
Bergamo 4
Gavirate 4
Hangzhou 4
Kiev 4
Norwalk 4
Philadelphia 4
Rieti 4
San Mateo 4
Siena 4
Washington 4
Asti 3
Bologna 3
Budapest 3
Chions 3
Falls Church 3
Hanoi 3
Magnago 3
Ningbo 3
Padova 3
Pavia 3
Rome 3
Annone di Brianza 2
Bovisio Masciago 2
Cambiago 2
Cermenate 2
Chicago 2
Como 2
Daejeon 2
Eugene 2
Fano 2
Gallarate 2
Hefei 2
Montréal 2
Nürnberg 2
Phoenix 2
Pomigliano d'Arco 2
San Fili 2
San Rocco 2
Shaoxing 2
Verona 2
Villa Cortese 2
Aarhus 1
Totale 4.509
Nome #
A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation 522
Combinations of a btk inhibitor and fluorouracil for treating cancers 486
Inhibition of GSK3B Bypass Drug Resistance of p53-null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy 472
Pharmaceutical kit for use in the treatment of colon and colorectal cancer 446
GSK3A Is Redundant with GSK3B in Modulating Drug Resistance and Chemotherapy-Induced Necroptosis 411
BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers 349
Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype 336
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma 299
Simultaneous overexpression of human E5NT and ENTPD1 protects porcine endothelial cells against H2O2-induced oxidative stress and cytotoxicity in vitro 285
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 272
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer 238
Unexpected frequency of genomic alterations in histologically normal colonic tissue from colon cancer patients 175
The antiangiogenic effect of the metronomic combination of 5-Fluorouracil plus vinorelbine is mediated by FAK/AKT pathway downregulation and apoptosis activation 162
The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells 148
Methods for determining the sensitivity or resistance of cancer cells to at least one anticancer drug and/or therapeutically active molecule 130
Isoform of bruton's tyrosine kinase (BTK) protein 124
Btk inhibitors for use in treating chemotherapeutic drug-resistant epithelial tumours 124
Isoform of Bruton's tyrosine kinase (BTK) protein 123
Isoform of bruton's tyrosine kinase (BTK) protein 118
Modulator compounds of the drug resistance in epithelial tumour cells 116
Modulator compounds of the drug resistance in epithelial tumour cells 112
BTK Isoforms p80 and p65 Are Expressed in Head and Neck Squamous Cell Carcinoma (HNSCC) and Involved in Tumor Progression 100
Modulator compounds of the drug resistance in epithelial tumour cells 99
NEW ISOFORM OF BRUTON’S TYROSINE KINASE (BTK) PROTEIN 98
Modulator compound of the drug resistance in epithelial tumor cells 78
Emerging actionable targets to treat therapy-resistant colorectal cancers 75
p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors 73
Editorial: Targeting Bruton Tyrosine Kinase 55
Identifying novel actionable targets in colon cancer 51
BTK, the new kid on the (oncology) block? 40
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation 25
"Ironing out" fasting-induced persister cancer cells to render chemotherapy effective: is this the solution? 25
Totale 6.167
Categoria #
all - tutte 11.548
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.548


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019283 0 0 0 0 0 34 35 39 41 46 25 63
2019/20201.067 78 62 87 72 95 130 136 85 103 105 102 12
2020/20211.359 67 29 135 128 122 135 134 139 110 145 98 117
2021/2022639 90 83 96 57 24 40 25 16 18 12 79 99
2022/20231.414 126 288 145 115 85 142 88 108 102 73 83 59
2023/2024482 78 74 89 109 93 39 0 0 0 0 0 0
Totale 6.167